JP2001500878A - オランザピン二水和物d - Google Patents
オランザピン二水和物dInfo
- Publication number
- JP2001500878A JP2001500878A JP10514881A JP51488198A JP2001500878A JP 2001500878 A JP2001500878 A JP 2001500878A JP 10514881 A JP10514881 A JP 10514881A JP 51488198 A JP51488198 A JP 51488198A JP 2001500878 A JP2001500878 A JP 2001500878A
- Authority
- JP
- Japan
- Prior art keywords
- dihydrate
- formulation
- olanzapine
- polymorph
- substantially pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.表1に記載の面間隔(d)によって表される典型的なX線粉末回折パターン を有する二水和物Dオランザピン多形体: 2.実質的に以下のX線粉末回折パターン(表中、dは面間隔を表し、I/I1 は典型的な相対強度を表す)によってさらに特徴付けられる請求項1に記載の二 水和物D多形体: 3.二水和物Dが実質的に純粋である請求項1に記載の二水和物D。 4.二水和物Dが実質的に純粋である請求項2に記載の二水和物D。 5.「実質的に純粋」が、表2に記載の面間隔(d)によって表される典型的な X線粉末回折パターンを有する二水和物Bが2%より少ないことを意味する請求 項2に記載の二水和物D: 6.二水和物Dが医薬的に優れた安定な結晶多形体である請求項1に記載の二水 和物D。 7.二水和物Dが医薬的に優れた安定な結晶多形体である請求項2に記載の二水 和物D。 8.1つまたはそれ以上の製薬的に許容される担体、希釈剤または賦形剤ととも に請求項1に記載の化合物を活性成分として含む医薬製剤。 9.1つまたはそれ以上の製薬的に許容される担体、希釈剤または賦形剤ととも に請求項2に記載の化合物を活性成分として含む医薬製剤。 10.製剤が水性懸濁剤である請求項8に記載の製剤。 11.製剤が錠剤である請求項8に記載の製剤。 12.1つまたはそれ以上の製薬的に許容される担体、希釈剤または賦形剤とと もに請求項3に記載の化合物を活性成分として含む医薬製剤。 13.製剤が水性懸濁剤である請求項12に記載の製剤。 14.請求項1に記載の化合物の有効量を投与することを特徴とする哺乳類の精 神病症状の処置方法。 15.請求項1に記載の化合物の有効量を投与することを特徴とする哺乳類の不 安、精神分裂症、精神分裂症様疾患、機能的腸疾患および精神病からなる群から 選択される症状の処置方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2648696P | 1996-09-23 | 1996-09-23 | |
US60/026,486 | 1996-09-23 | ||
PCT/US1997/016586 WO1998011893A1 (en) | 1996-09-23 | 1997-09-18 | Olanzapine dihydrate d |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001500878A true JP2001500878A (ja) | 2001-01-23 |
JP2001500878A5 JP2001500878A5 (ja) | 2005-05-12 |
Family
ID=21832112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10514881A Withdrawn JP2001500878A (ja) | 1996-09-23 | 1997-09-18 | オランザピン二水和物d |
Country Status (35)
Country | Link |
---|---|
US (1) | US6251895B1 (ja) |
EP (1) | EP0831097B1 (ja) |
JP (1) | JP2001500878A (ja) |
KR (1) | KR100516088B1 (ja) |
CN (1) | CN1146567C (ja) |
AR (1) | AR009801A1 (ja) |
AT (1) | ATE221074T1 (ja) |
AU (1) | AU720366B2 (ja) |
BR (1) | BR9711541A (ja) |
CA (1) | CA2266444C (ja) |
CO (1) | CO4900057A1 (ja) |
CZ (1) | CZ299247B6 (ja) |
DE (1) | DE69714165T2 (ja) |
DK (1) | DK0831097T3 (ja) |
EA (1) | EA001881B1 (ja) |
EG (1) | EG23815A (ja) |
ES (1) | ES2180899T3 (ja) |
HK (1) | HK1009809A1 (ja) |
HU (1) | HU226167B1 (ja) |
ID (1) | ID21924A (ja) |
IL (1) | IL128956A0 (ja) |
MY (1) | MY125467A (ja) |
NO (1) | NO323979B1 (ja) |
NZ (1) | NZ334346A (ja) |
PE (1) | PE110298A1 (ja) |
PL (1) | PL194074B1 (ja) |
PT (1) | PT831097E (ja) |
RS (1) | RS49597B (ja) |
SI (1) | SI0831097T1 (ja) |
SV (1) | SV1997000079A (ja) |
TR (1) | TR199900639T2 (ja) |
TW (1) | TW518335B (ja) |
UA (1) | UA56184C2 (ja) |
WO (1) | WO1998011893A1 (ja) |
ZA (1) | ZA978512B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009242407A (ja) * | 1996-09-23 | 2009-10-22 | Eli Lilly & Co | オランザピンの製造方法および中間体 |
WO2014080784A1 (ja) * | 2012-11-20 | 2014-05-30 | 大蔵製薬株式会社 | 長期間安定なオランザピンの水性医薬製剤 |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
CZ302367B6 (cs) * | 1998-09-30 | 2011-04-13 | Eli Lilly And Company | 2-Methylthienobenzodiazepinový prípravek |
NZ519926A (en) * | 1999-12-28 | 2004-02-27 | Cipla Ltd | New polymorphic forms of olanzapine |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
IL154688A0 (en) * | 2000-08-31 | 2003-09-17 | Reddys Lab Ltd Dr | Hydrates of olanzapine and processes for the preparation thereof |
US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
CA2464306A1 (en) * | 2001-10-29 | 2003-05-08 | Dr. Reddy's Laboratories Ltd. | Olanzapine dihydrate-ii a process for its preparation and use thereof |
ATE500258T1 (de) | 2002-05-31 | 2011-03-15 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7323459B2 (en) * | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
ES2289974T1 (es) * | 2004-07-14 | 2008-02-16 | Shasun Chemicals And Drugs Limited | Metodo mejorado para producir la forma i de la olanzapina. |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE112005000641T5 (de) | 2004-09-06 | 2007-09-06 | Shasun Chemicals and Drugs Ltd., Chennai | Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
BRPI0518187A (pt) * | 2004-11-16 | 2008-11-04 | Elan Pharma Int Ltd | formulações de olanzapina em nanopartìcula injetáveis |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
WO2006073886A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
US7834176B2 (en) * | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
CA2724533C (en) * | 2008-07-24 | 2014-07-29 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP3024464A1 (en) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Treatment of myelodysplastic syndrome |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
ATE198891T1 (de) * | 1992-05-29 | 2001-02-15 | Lilly Co Eli | Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems |
BR9508136A (pt) | 1994-06-28 | 1997-11-25 | Grace W R & Co | Bolsas tendo remendos protetores |
EP0733368A1 (en) * | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Granule fomulation for olanzapine |
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
-
1997
- 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Application Discontinuation
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active IP Right Cessation
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
-
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
- 1998-09-21 HK HK98110803A patent/HK1009809A1/xx not_active IP Right Cessation
-
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009242407A (ja) * | 1996-09-23 | 2009-10-22 | Eli Lilly & Co | オランザピンの製造方法および中間体 |
WO2014080784A1 (ja) * | 2012-11-20 | 2014-05-30 | 大蔵製薬株式会社 | 長期間安定なオランザピンの水性医薬製剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001500878A (ja) | オランザピン二水和物d | |
KR100399688B1 (ko) | 2-메틸-티에노-벤조디아제핀의결정형및그의제조방법 | |
EP0277738B1 (en) | Anhdrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide | |
JP2001500877A (ja) | オランザピンの製造方法および中間体 | |
JP2001517684A (ja) | 性機能不全を処置するための方法 | |
JP2000506860A (ja) | 自閉症の処置方法 | |
US20070259857A1 (en) | Amorphous form of Olanzapine | |
HUT77907A (hu) | 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására | |
JP2000506858A (ja) | 過剰攻撃性の処置方法 | |
MXPA97007183A (en) | A process and glass forms of 2-methyl-tieno-benzodiazep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080718 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080901 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080821 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080919 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081027 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090203 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090424 |